FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322719474> ?p ?o ?g. }

• W4322719474 endingPage "456" @default.
• W4322719474 startingPage "456" @default.
• W4322719474 abstract "There is a need for a new, less invasive breast reconstruction option for patients who undergo mastectomy in their breast cancer treatment.To investigate quality of life (QoL) among patients undergoing a new breast reconstruction technique, autologous fat transfer (AFT), compared with that among patients undergoing implant-based reconstruction (IBR).The BREAST trial was a randomized clinical trial conducted between November 2, 2015, and October 31, 2021, performed in 7 hospitals across the Netherlands. Follow-up was 12 months. Referrals could be obtained from general practitioners and all departments from participating or nonparticipating hospitals. The patients with breast cancer who had undergone mastectomy and were seeking breast reconstruction were screened for eligibility (radiotherapy history and physique) by participating plastic surgeons. Patients receiving postmastectomy radiotherapy were excluded.Breast reconstruction with AFT plus expansion or 2-phased IBR. Randomization was done in a 1:1 ratio.The statistical analysis was performed per protocol. The predefined primary outcome was QoL at 12 months after final surgery. This was measured by the BREAST-Q questionnaire, a validated breast reconstruction surgery questionnaire. Questions on the BREAST-Q questionnaire are scored from 0 to 100, with a higher score indicating greater satisfaction or better QoL (depending on the scale). Secondary outcomes were breast volume and the safety and efficacy of the techniques.A total of 193 female patients (mean [SD] age, 49.2 [10.6] years) 18 years or older who desired breast reconstruction were included, of whom 91 patients in the AFT group (mean [SD] age, 49.3 [10.3] years) and 80 in the IBR group (mean age, 49.1 [11.0] years) received the allocated intervention. In total, 64 women in the AFT group and 68 women in the IBR group completed follow-up. In the IBR group, 18 patients dropped out mainly due to their aversion to implant use while in the AFT group 6 patients ended their treatment prematurely because of the burden (that is, the treatment being too heavy or tiring). The BREAST-Q scores were higher in the AFT group in all 5 domains and significantly higher in 3: satisfaction with breasts (difference, 9.9; P = .002), physical well-being: chest (difference; 7.6; P = .007), and satisfaction with outcome (difference, 7.6; P = .04). Linear mixed-effects regression analysis showed that QoL change over time was dependent on the treatment group in favor of AFT. The mean (SD) breast volume achieved differed between the groups (AFT: 300.3 [111.4] mL; IBR: 384.1 [86.6] mL). No differences in oncological serious adverse events were found.This randomized clinical trial found higher QoL and an increase in QoL scores over time in the AFT group compared with the IBR group. No evidence was found that AFT was unsafe. This is encouraging news since it provides a third, less invasive reconstruction option for patients with breast cancer.ClinicalTrials.gov Identifier: NCT02339779." @default.
• W4322719474 created "2023-03-03" @default.
• W4322719474 creator A5007336328 @default.
• W4322719474 creator A5037460922 @default.
• W4322719474 creator A5038533404 @default.
• W4322719474 creator A5043864446 @default.
• W4322719474 creator A5070659933 @default.
• W4322719474 creator A5076856872 @default.
• W4322719474 creator A5088563110 @default.
• W4322719474 date "2023-05-01" @default.
• W4322719474 modified "2023-09-27" @default.
• W4322719474 title "Effect of Total Breast Reconstruction With Autologous Fat Transfer Using an Expansion Device vs Implants on Quality of Life Among Patients With Breast Cancer" @default.
• W4322719474 cites W1928027795 @default.
• W4322719474 cites W1972105758 @default.
• W4322719474 cites W1974075938 @default.
• W4322719474 cites W1979524230 @default.
• W4322719474 cites W1987365087 @default.
• W4322719474 cites W1990446689 @default.
• W4322719474 cites W1991286302 @default.
• W4322719474 cites W1996575748 @default.
• W4322719474 cites W1998297419 @default.
• W4322719474 cites W2008659706 @default.
• W4322719474 cites W2029964490 @default.
• W4322719474 cites W2037112812 @default.
• W4322719474 cites W2049525845 @default.
• W4322719474 cites W2134774645 @default.
• W4322719474 cites W2136109044 @default.
• W4322719474 cites W2149682802 @default.
• W4322719474 cites W2195309679 @default.
• W4322719474 cites W2318694763 @default.
• W4322719474 cites W2507695613 @default.
• W4322719474 cites W2518196679 @default.
• W4322719474 cites W2805877439 @default.
• W4322719474 cites W2806415185 @default.
• W4322719474 cites W2808862172 @default.
• W4322719474 cites W2809242083 @default.
• W4322719474 cites W2888009613 @default.
• W4322719474 cites W2890786262 @default.
• W4322719474 cites W2977554384 @default.
• W4322719474 cites W2982855465 @default.
• W4322719474 cites W3092512774 @default.
• W4322719474 cites W3097548962 @default.
• W4322719474 cites W3118018179 @default.
• W4322719474 cites W3134219233 @default.
• W4322719474 cites W3201383883 @default.
• W4322719474 cites W3214836937 @default.
• W4322719474 doi "https://doi.org/10.1001/jamasurg.2022.7625" @default.
• W4322719474 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36857058" @default.
• W4322719474 hasPublicationYear "2023" @default.
• W4322719474 type Work @default.
• W4322719474 citedByCount "1" @default.
• W4322719474 countsByYear W43227194742023 @default.
• W4322719474 crossrefType "journal-article" @default.
• W4322719474 hasAuthorship W4322719474A5007336328 @default.
• W4322719474 hasAuthorship W4322719474A5037460922 @default.
• W4322719474 hasAuthorship W4322719474A5038533404 @default.
• W4322719474 hasAuthorship W4322719474A5043864446 @default.
• W4322719474 hasAuthorship W4322719474A5070659933 @default.
• W4322719474 hasAuthorship W4322719474A5076856872 @default.
• W4322719474 hasAuthorship W4322719474A5088563110 @default.
• W4322719474 hasConcept C121608353 @default.
• W4322719474 hasConcept C126322002 @default.
• W4322719474 hasConcept C141071460 @default.
• W4322719474 hasConcept C159110408 @default.
• W4322719474 hasConcept C168563851 @default.
• W4322719474 hasConcept C204243189 @default.
• W4322719474 hasConcept C2777704003 @default.
• W4322719474 hasConcept C2777757722 @default.
• W4322719474 hasConcept C2779951463 @default.
• W4322719474 hasConcept C2781001896 @default.
• W4322719474 hasConcept C509974204 @default.
• W4322719474 hasConcept C530470458 @default.
• W4322719474 hasConcept C71924100 @default.
• W4322719474 hasConceptScore W4322719474C121608353 @default.
• W4322719474 hasConceptScore W4322719474C126322002 @default.
• W4322719474 hasConceptScore W4322719474C141071460 @default.
• W4322719474 hasConceptScore W4322719474C159110408 @default.
• W4322719474 hasConceptScore W4322719474C168563851 @default.
• W4322719474 hasConceptScore W4322719474C204243189 @default.
• W4322719474 hasConceptScore W4322719474C2777704003 @default.
• W4322719474 hasConceptScore W4322719474C2777757722 @default.
• W4322719474 hasConceptScore W4322719474C2779951463 @default.
• W4322719474 hasConceptScore W4322719474C2781001896 @default.
• W4322719474 hasConceptScore W4322719474C509974204 @default.
• W4322719474 hasConceptScore W4322719474C530470458 @default.
• W4322719474 hasConceptScore W4322719474C71924100 @default.
• W4322719474 hasIssue "5" @default.
• W4322719474 hasLocation W43227194741 @default.
• W4322719474 hasLocation W43227194742 @default.
• W4322719474 hasOpenAccess W4322719474 @default.
• W4322719474 hasPrimaryLocation W43227194741 @default.
• W4322719474 hasRelatedWork W2031214944 @default.
• W4322719474 hasRelatedWork W2094323122 @default.
• W4322719474 hasRelatedWork W2546448373 @default.
• W4322719474 hasRelatedWork W2883231437 @default.
• W4322719474 hasRelatedWork W2893653013 @default.
• W4322719474 hasRelatedWork W2988785535 @default.
• W4322719474 hasRelatedWork W3007051496 @default.

• next